{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000145","form_type":"8-K","ticker":"BBNX","cik":"0001674632","company_name":"Beta Bionics, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.856409+00:00","generated_at":"2026-05-16T11:13:15.781592+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Beta Bionics preliminary Q4 2025 net sales ≥$32M, up >56% YoY; installed base >35K","bullets":["Net sales expected ≥$32.0M, up >56% from $20.4M in Q4 2024.","DME channel net sales ≥$22.3M (+23% YoY); PBP channel ≥$9.7M (+308% YoY).","Installed customer base ≥35,000 users (+128% YoY); new patient starts ≥5,581 (+36% YoY).","~69% of new starts from multiple daily injections; 25-30% are type 2 diabetes patients.","Full Q4 and FY 2025 results to be reported Feb 17, 2026; conference call scheduled."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000145","json":"https://secwatch.observer/filing/0001171843-26-000145.json","markdown":"https://secwatch.observer/filing/0001171843-26-000145.md","text":"https://secwatch.observer/filing/0001171843-26-000145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674632/000117184326000145/0001171843-26-000145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674632/000117184326000145/f8k_010726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:13:15.781592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}